down-chev
down-chev

WE ARE A PRECISION DRUG DEVELOPMENT COMPANY FOCUSED ON ONCOLOGY

Our purpose is to accelerate the development of cancer medicines and treatments

Rewriting Cancer

We are delighted to announce our involvement in Rewriting Cancer, a series produced for UICC by BBC StoryWorks Commercial Productions. This unique project examines the complexity of cancer and the changes in treatments that are required to achieve better outcomes for patients. Watch and learn how we and the other participants are Rewriting Cancer. In oncology we all share a common goal to improve the lives of patients.

Talk to our team

We’d like to hear from you

Read the latest news from Ellipses Pharma

EP0031 Poster ASCO 2025

EP0031 Poster ASCO 2025 {{ vc_btn: title=Download+larger+version&style=custom&custom_background=%23000066&custom_text=%23ffffff&shape=round&size=lg&align=center&css=.vc_custom_1749190534045%7Bpadding-top%3A+15px+%21important%3B%7D&link=url%3Ahttps%253A%252F%252Fellipses.life%252Fwp-content%252Fuploads%252F2025%252F06%252FEP0031_Poster_ASCO_2025.pdf%7Ctarget%3A_blank }} About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise the time [...]

EP0062 Poster ASCO 2025

EP0062 Poster ASCO 2025 {{ vc_btn: title=Download+larger+version&style=custom&custom_background=%23000066&custom_text=%23ffffff&shape=round&size=lg&align=center&css=.vc_custom_1749120535965%7Bpadding-top%3A+15px+%21important%3B%7D&link=url%3Ahttps%253A%252F%252Fellipses.life%252Fwp-content%252Fuploads%252F2025%252F06%252FEP0062_Poster_ASCO_2025.pdf%7Ctarget%3A_blank }} About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise the time [...]

Ellipses In-Licences First in Class Novel Immuno-Oncology Agent

Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next Generation Checkpoint Inhibitor London, February 11, 2025: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it is to develop a next-generation immuno-oncology drug which could [...]